Sunitinib in Combination With Temsirolimus for mRCC

March 8, 2014
Nizar M. Tannir, MD, FACP

Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Nizar M. Tannir, MD, FACP, associate professor, deputy department chair, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses a phase I trial of sunitinib and temsirolimus in patients with metastatic renal cell carcinoma.

Clinical Pearls:

  • This combination was previously studied, though it was found to be “not viable”
  • A phase I study, which accrued 20 patients, found that the two agents could be combined
  • Results of this trial showed that temsirolimus must be reduced to 8 or 10 mg weekly in order to maintain the 37.5-mg dosing of sunitinib